 Nicholas Di bella
Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell | 3 | 2009 | 141 | 0.510 |
Why?
| | Dasatinib | 1 | 2015 | 58 | 0.440 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 128 | 0.410 |
Why?
| | Pyrimidines | 1 | 2015 | 530 | 0.340 |
Why?
| | Antineoplastic Agents | 4 | 2015 | 2219 | 0.320 |
Why?
| | Boronic Acids | 1 | 2009 | 36 | 0.300 |
Why?
| | Pyrazines | 1 | 2009 | 94 | 0.280 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 981 | 0.280 |
Why?
| | Purine Nucleosides | 1 | 2006 | 4 | 0.240 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2005 | 124 | 0.220 |
Why?
| | Lymphoma | 1 | 2006 | 241 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 1969 | 0.180 |
Why?
| | Doxorubicin | 1 | 2003 | 403 | 0.160 |
Why?
| | Disease-Free Survival | 3 | 2015 | 770 | 0.160 |
Why?
| | Polyethylene Glycols | 1 | 2003 | 649 | 0.130 |
Why?
| | Pentostatin | 3 | 2011 | 4 | 0.130 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2011 | 76 | 0.130 |
Why?
| | Peptides | 1 | 2003 | 1000 | 0.120 |
Why?
| | Treatment Outcome | 7 | 2015 | 11794 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 971 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 3 | 2011 | 95 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2009 | 883 | 0.090 |
Why?
| | Rituximab | 3 | 2011 | 210 | 0.080 |
Why?
| | Medication Adherence | 1 | 2015 | 540 | 0.080 |
Why?
| | Aged | 7 | 2015 | 26217 | 0.080 |
Why?
| | Bortezomib | 1 | 2009 | 54 | 0.080 |
Why?
| | Middle Aged | 8 | 2015 | 36309 | 0.070 |
Why?
| | Salvage Therapy | 1 | 2009 | 165 | 0.070 |
Why?
| | Recurrence | 2 | 2009 | 1139 | 0.070 |
Why?
| | Adult | 8 | 2015 | 40882 | 0.070 |
Why?
| | Hodgkin Disease | 2 | 2004 | 172 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2011 | 8347 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2005 | 1505 | 0.060 |
Why?
| | Survival Analysis | 1 | 2009 | 1378 | 0.060 |
Why?
| | Lymphoma, Follicular | 1 | 2006 | 56 | 0.060 |
Why?
| | Mitoxantrone | 1 | 2005 | 15 | 0.060 |
Why?
| | Disease Progression | 2 | 2009 | 2865 | 0.050 |
Why?
| | Male | 8 | 2015 | 73012 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2004 | 220 | 0.050 |
Why?
| | Female | 8 | 2015 | 79045 | 0.050 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2003 | 43 | 0.050 |
Why?
| | Liposomes | 1 | 2003 | 263 | 0.040 |
Why?
| | Humans | 9 | 2015 | 145785 | 0.040 |
Why?
| | Survival Rate | 1 | 2005 | 2094 | 0.040 |
Why?
| | Pilot Projects | 1 | 2005 | 1898 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2003 | 1475 | 0.040 |
Why?
| | Young Adult | 1 | 2015 | 14254 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2015 | 17330 | 0.030 |
Why?
| | Adolescent | 2 | 2015 | 22577 | 0.030 |
Why?
| | Prognosis | 1 | 2003 | 4330 | 0.030 |
Why?
| | Splenectomy | 1 | 1973 | 61 | 0.020 |
Why?
| | Radiotherapy | 1 | 1973 | 206 | 0.020 |
Why?
| | Vidarabine | 1 | 2011 | 32 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2011 | 272 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2004 | 106 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2004 | 298 | 0.010 |
Why?
| | Time Factors | 2 | 2004 | 7134 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2003 | 140 | 0.010 |
Why?
| | Child | 1 | 1973 | 22740 | 0.000 |
Why?
|
|
Di bella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|